Market News & Trends
Enable Injections & Flex Partner for Production of Wearable High-Volume Injectors
Enable Injections Inc. recently announced it has entered into a product development and manufacturing partnership with Flex. As part of the deal, Enable Injections and…
Dipexium Reaches 75% Enrollment Milestone in Pivotal Phase III Trials
Dipexium Pharmaceuticals, Inc. recently announced its OneStep-1 and OneStep-2 pivotal Phase III clinical trials have reached the 75% enrollment milestone, in the aggregate, with each…
Albumedix & Eleven Biotherapeutics Announce Albumin Variant Technology Agreement
Eleven Biotherapeutics, Inc. and Albumedix recently announced they have entered into an agreement that will see Albumedix acquire Eleven’s proprietary Supermin albumin variant assets. Albumedix…
Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions
Lonza recently announced that its Pharma & Biotech segment is expanding its footprint to offer customers a complete portfolio of development and manufacturing services for…
Fibrocell Science Highlights Recent Pipeline Accomplishments
Fibrocell Science, Inc. recently highlighted several recent accomplishments related to the continued advancement of the company’s pipeline. “Recently, Fibrocell has made significant progress across our…
Trillium Therapeutics Acquires Fluorinov Pharma
FACIT has announced that Trillium Therapeutics Inc. has acquired all of the outstanding shares of privately held Fluorinov Pharma Inc., a FACIT portfolio company. The…
Sernova Announces Agreement With CCRM to Produce Specialized Cells for Diabetes Treatment
Sernova Corp recently announced it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize, and validate…
Noxilizer Announces New Senior Vice President & CFO
Noxilizer, Inc., the company advancing a room temperature, NO2-based sterilization and decontamination process for biopharmaceutical and medical device manufacturers recently announced David A. Theil as…
AbCellera & Merck Sign Novel Therapeutic Antibody Discovery Collaboration
AbCellera recently announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an…
Catalent & Cerenis Therapeutics Announce Phase III Trial of CER-001
Catalent Pharma Solutions recently announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.…